Form 4: Tandem Diabetes Care CEO John F. Sheridan Reports Stock Transactions

Sentiment:

SEC Form 4


John F. Sheridan, CEO of Tandem Diabetes Care, reports the vesting and subsequent tax withholding of performance stock units.

Summary

  • On February 25, 2025, John F. Sheridan, the President and CEO of Tandem Diabetes Care Inc., reported transactions involving the company's common stock.
  • Sheridan acquired 6,732 shares and 26,047 shares of common stock through the vesting of performance stock units (PSUs).
  • The shares were acquired at a price of $0.
  • Tandem Diabetes Care, Inc. withheld 3,419 shares and 10,008 shares to satisfy tax withholding requirements at a price of $33.34.
  • Following these transactions, Sheridan directly owns 79,009 shares of Tandem Diabetes Care Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, and does not inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the healthcare and medical device industry.

Stakeholder Impact

  • The transactions have a minor impact on shareholders as they reflect executive compensation and ownership changes.

Key Dates

DateDescription
May 18, 2021Date of PSU award pursuant to the 2013 Stock Incentive Plan.
May 25, 2022Date of PSU award pursuant to the 2013 Stock Incentive Plan.
December 31, 2024Measurement Date for performance metrics related to the PSUs.
February 25, 2025Date of stock transactions (vesting of PSUs and tax withholding).
February 27, 2025Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.